Edit
Nitrome Biosciences
http://nitromebiosciences.com/Last activity: 02.11.2021
Active - Reference to Nitrase Therapeutics
Nitrome Biosciences is a platform company developing drugs against a newly identified class of enzymes called Nitrases, initially targeting Parkinson’s disease. The therapies that Nitrome is developing will target these enzymes and potentially help slow or halt the progression of diseases such as Parkinson’s. While the initial focus is on Parkinson's disease, the company aims to expand its proprietary platform to include other disease indications. Nitrome has been widely recognized, and has won multiple awards including the prestigious Target Advancement grant from The Michael J. Fox Foundation for Parkinson's Research (MJFF). For more information, please visit our website at www.nitromebiosciences.com.
Total raised: $38M
Investors 3
| Date | Name | Website |
| - | Sofinnova ... | sofinnovap... |
| 15.09.2024 | Breakthrou... | breakthrou... |
| - | MBC BioLab... | mbcbiolabs... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 20.05.2020 | Series A | $38M | - |
Mentions in press and media 8
| Date | Title | Description |
| 02.11.2021 | Nitrome Biosciences Appoints Pierre Beaurang, Ph.D., as Chief Executive Officer, Expands Series A to $45M, and Changes Company Name to Nitrase Therapeutics | --Founder Irene Griswold-Prenner, Ph.D., Focuses on Role as Chief Scientific Officer— |
| 02.11.2021 | Nitrome Biosciences Appoints Pierre Beaurang, Ph.D., as Chief Executive Officer, Expands Series A to $45M, and Changes Company Name to Nitrase Therapeutics | SAN FRANCISCO, Nov. 02, 2021 (GLOBE NEWSWIRE) -- Nitrase Therapeutics, Inc. (formerly Nitrome Biosciences), a biopharmaceutical company deploying its unique NITROME platform to unlock the therapeutic potential of nitrases, a new class of en... |
| 02.11.2021 | Nitrome Biosciences Appoints Pierre Beaurang, Ph.D., as Chief Executive Officer, Expands Series A to $45M, and Changes Company Name to Nitrase Therapeutics | Founder Irene Griswold-Prenner, Ph.D., Focuses on Role as Chief Scientific Officer SAN FRANCISCO, Nov. 02, 2021 (GLOBE NEWSWIRE) -- Nitrase Therapeutics, Inc. (formerly Nitrome Biosciences), a biopharmaceutical company deploying its unique ... |
| 20.05.2020 | Nitrome Biosciences Raises $38M Series A Financing | - |
| 24.04.2020 | Nitrome Biosciences Raises $38M Series A | SAN FRANCISCO, CA, Nitrome Biosciences has closed a Series A financing of $38 million co-led by Sofinnova Partners and AbbVie Ventures. >> Click here for more funding data on Nitrome Biosciences >> To export Nitrome Bioscien... |
| 23.04.2020 | Nitrome Biosciences Raises $38M Series A Financing to Advance Therapeutics Targeting a Novel Group of Enzymes involved in Age-related Diseases | |
| 22.04.2020 | Nitrome Biosciences Raises $38M in Series A Financing | Nitrome Biosciences, a San Francisco, CA-based biopharmaceutical company developing a platform around a newly identified class of enzymes to target Parkinson’s disease and other age-related disorders, closed a $38m Series A financing. The r... |
| 21.04.2020 | Nitrome Biosciences Raises $38M Series A | SAN FRANCISCO--(BUSINESS WIRE)--Nitrome Biosciences (Nitrome), a privately-held biopharmaceutical company developing a platform around a newly identified class of enzymes to target Parkinson’s disease and other age-related disorders, today ... |